🇪🇺 Yorvipath in European Union

EMA authorised Yorvipath on 17 November 2023

Marketing authorisation

EMA — authorised 17 November 2023

  • Application: EMEA/H/C/005934
  • Marketing authorisation holder: Ascendis Pharma Bone Diseases A/S
  • Local brand name: Yorvipath
  • Indication: Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
  • Pathway: orphan
  • Status: approved

Read official source →

Yorvipath in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Nephrology approved in European Union

Frequently asked questions

Is Yorvipath approved in European Union?

Yes. EMA authorised it on 17 November 2023.

Who is the marketing authorisation holder for Yorvipath in European Union?

Ascendis Pharma Bone Diseases A/S holds the EU marketing authorisation.